Skip To Main Content

Expert group consensus from the Arabian Peninsula on the diagnosis of LOPD

Objective and Method

Consensus based on literature supporting clinical presentation and recommendations

Literature Analysis on LOPD Symptoms (Rheumatology): Hierarchy of Evidence


 

  • Systemic review and meta-analysis
  • Randomized controlled trials
  • Observational studies (cohort studies/screening studies)
  • Case series studies
  • Case series, case reports
  • Expert Opinion





 

  • 11 studies for adult# LOPD

Rheumatology-Specific

Clinical Presentation for Adult# LOPD Proposed During the First Meeting

  • Unexplained general/inflammatory myopathy
  • Asymptomatic hyperCKemia/paucisymptomatic
  • Unexplained LGMW
  • Polymyositis non-responding to steroids

 

High CK/elevated
LDH, ALT, and AST

Rheumatology-Specific Diagnostic Algorithm Proposed During the Second Meeting

Conclusion

A consensus-based diagnostic algorithm simplifies LOPD diagnosis across specialties

  • Guides clinicians in the differential diagnosis of LOPD
  • Facilitates direct referral for early and accurate diagnosis of LOPD

Recommendation

Testing for Pompe disease must be done if any one specialty-specific symptom plus elevated CK/LDH/ALT/AST or a family history of unexplained muscle weakness are present.

Conclusion

*The age of patients with pediatric/juvenile LOPD ranges from 1 to 17 years; #The age of patients with adult LOPD is usually 18 years and above.

Abbreviations

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CK: Creatine kinase; DBS: Dried blood spot testing; DMD: Duchenne muscular dystrophy; KSA: Kingdom of Saudi Arabia; LDH: Lactate dehydrogenase; LGMW: Limb–girdle muscle weakness; LOPD: Late-onset Pompe disease; MG: Myasthenia gravis; SMA: Spinal muscular atrophy; UAE: United Arab Emirates.

Reference

  1. Al Shehri A, Al-Asmi A, Al Salti AM, et al. A multidisciplinary perspective addressing the diagnostic challenges of late-onset Pompe disease in the Arabian Peninsula region developed from an Expert Group Meeting. J Neuromuscul Dis. 2022;9(5):661–673.
MAT-BH-2300387-V1-MAY 2023